Decibel Therapeutics has filed with the US Securities and Exchange Commission to raise up to $75 million in an initial public offering, as reported in NASDAQ.
Its lead gene therapy product candidate, DB-OTO, is being developed to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene.
According to the news source, Decibel's platform integrates single-cell genomics and bioinformatics analyses, using precision gene therapy technologies to advance a pipeline of preclinical gene therapy programs designed to selectively replace genes for the treatment of congenital, monogenic hearing loss.
The company is also advancing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, and DB-020, which is for the prevention of cisplatin-induced hearing loss and is currently being evaluated in a Phase Ib trial.
To read more NewsPoints articles, click here.